News
We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...
Regeneron Pharma is currently 0.35% higher at $596.39 on Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq ...
Regeneron Pharmaceuticals (NASDAQ:REGN) will buy substantially all assets of genetic testing firm 23andMe for a purchase pric ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced today that it will acquire 23andMe for a purchase price of $256 ...
Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...
4d
InvestorsHub on MSNRegeneron Shares Climb on Acquisition of 23andMe Assets in Bankruptcy DealRegeneron Pharmaceuticals (NASDAQ:REGN) saw its stock rise 2% after announcing it had secured a winning bid to acquire key ...
Source: Regeneron Pharmaceuticals, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our ...
In children aged 8 to 11 years, PRALUENT should be given by a caregiver. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming ...
We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...
A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...
Me, known for its at-home DNA testing kits, is expected to be obtained by its highest bidder following a bankruptcy auction ...
Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results